{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:08:25Z","timestamp":1777478905086,"version":"3.51.4"},"reference-count":60,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:p>COVID-19 has proven to be particularly challenging given the complex pathogenesis of SARS-CoV-2. Early data have demonstrated how the host response to this novel coronavirus leads to the proliferation of pro-inflammatory cytokines, massive endothelial damage, and generalized vascular manifestations. While SARS-CoV-2 primarily targets the upper and lower respiratory tract, other organ systems are also affected. SARS-CoV-2 relies on 2 host cell receptors for successful attachment: angiotensin-converting enzyme 2 and transmembrane protease serine 2. Clinicopathologic reports have demonstrated associations between severe COVID-19 and viral coagulopathy, resulting in pulmonary embolism; venous, arterial, and microvascular thrombosis; lung endothelial injury; and associated thrombotic complications leading to acute respiratory distress syndrome. Viral coagulopathy is not novel given similar observations with SARS classic, including the consumption of platelets, generation of thrombin, and increased fibrin degradation product exhibiting overt disseminated intravascular coagulation\u2013like syndrome. The specific mechanism(s) behind the thrombotic complications in COVID-19 patients has yet to be fully understood. Parenteral anticoagulants, such as heparin and low-molecular-weights heparins, are widely used in the management of COVID-19 patients. Beyond the primary (anticoagulant) effects of these agents, they may exhibit antiviral, anti-inflammatory, and cytoprotective effects. Direct oral anticoagulants and antiplatelet agents are also useful in the management of these patients. Tissue plasminogen activator and other fibrinolytic modalities may also be helpful in the overall management. Catheter-directed thrombolysis can be used in patients developing pulmonary embolism. Further investigations are required to understand the molecular and cellular mechanisms involved in the pathogenesis of COVID-19-associated thrombotic complications.<\/jats:p>","DOI":"10.1177\/1076029620936776","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T13:03:58Z","timestamp":1595250238000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":68,"title":["Viral Coagulopathy in Patients With COVID-19: Treatment and Care"],"prefix":"10.1177","volume":"26","author":[{"given":"Nickolas","family":"Kipshidze","sequence":"first","affiliation":[{"name":"NY Cardiovascular Research, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Dangas","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"White","sequence":"additional","affiliation":[{"name":"Ochsner Clinical School, University of Queensland, AU and Ochsner Medical Center, New Orleans, LA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nodar","family":"Kipshidze","sequence":"additional","affiliation":[{"name":"NYU Langone Health, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2219-7049","authenticated-orcid":false,"given":"Fakiha","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cardiovascular Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Lattimer","sequence":"additional","affiliation":[{"name":"London Northwest University Health Care NHS Trust, London, United Kingdom"},{"name":"Imperial College of Science, Technology and Medicine, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-0402","authenticated-orcid":false,"given":"Charles A.","family":"Carter","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, College of Pharmacy & Health Sciences, Campbell University, Buies Creek, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3465-2499","authenticated-orcid":false,"given":"Jawed","family":"Fareed","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Cardiovascular Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA"},{"name":"Department of Pharmacology and Neuroscience, Cardiovascular Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"bibr1-1076029620936776","doi-asserted-by":"crossref","unstructured":"Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061\u20131069. https:\/\/doi.org\/10.1001\/jama.2020.1585","DOI":"10.1001\/jama.2020.1585"},{"key":"bibr2-1076029620936776","doi-asserted-by":"crossref","unstructured":"Young BE, Ong S, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488\u20131494. https:\/\/doi.org\/10.1001\/jama.2020.3204","DOI":"10.1001\/jama.2020.3204"},{"key":"bibr3-1076029620936776","doi-asserted-by":"crossref","unstructured":"Hoffmann M, Weber HK, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271\u2013280.e8. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"bibr4-1076029620936776","doi-asserted-by":"crossref","unstructured":"Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631\u2013637. https:\/\/doi.org\/10.1002\/path.1570","DOI":"10.1002\/path.1570"},{"key":"bibr5-1076029620936776","doi-asserted-by":"crossref","unstructured":"Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843\u20131844. https:\/\/doi.org\/10.1001\/jama.2020.3786","DOI":"10.1001\/jama.2020.3786"},{"key":"bibr6-1076029620936776","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH743>3.0.CO;2-T"},{"key":"bibr7-1076029620936776","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2015432"},{"key":"bibr8-1076029620936776","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2018629"},{"key":"bibr9-1076029620936776","first-page":"e208907","author":"Schaller T","year":"2020","journal-title":"JAMA"},{"key":"bibr10-1076029620936776","doi-asserted-by":"crossref","unstructured":"Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Hemost. 2020;18(5):1023\u20131026. https:\/\/doi.org\/10.1111\/jth.14810","DOI":"10.1111\/jth.14810"},{"key":"bibr11-1076029620936776","doi-asserted-by":"crossref","unstructured":"Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Modern pathol. 2005;18(1):1\u201310. https:\/\/doi.org\/10.1038\/modpathol.3800247","DOI":"10.1038\/modpathol.3800247"},{"key":"bibr12-1076029620936776","doi-asserted-by":"crossref","unstructured":"Yang M, Ng MH, Li CK. Thrombocytopenia in patients with severe acute respiratory syndrome (review). Hematology. 2005;10(2):101\u2013105. https:\/\/doi.org\/10.1080\/10245330400026170","DOI":"10.1080\/10245330400026170"},{"key":"bibr13-1076029620936776","doi-asserted-by":"crossref","unstructured":"Hastings PRS, Krewski D. Reviewing the history of pandemic influenza: understanding patterns of emergence and transmission. Pathogens. 2016;5(4):66. https:\/\/doi.org\/10.3390\/pathogens5040066","DOI":"10.3390\/pathogens5040066"},{"key":"bibr14-1076029620936776","doi-asserted-by":"crossref","unstructured":"Harms PW, Schmidt LA, Smith LB, et al. Autopsy findings in eight patients with fatal H1N1 influenza. Am J Clin Pathol. 2010;134(1):27\u201335. https:\/\/doi.org\/10.1309\/AJCP35KOZSAVNQZW","DOI":"10.1309\/AJCP35KOZSAVNQZW"},{"key":"bibr15-1076029620936776","doi-asserted-by":"crossref","unstructured":"Mauad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Resp Crit Care Med. 2010;181(1):72\u201379. https:\/\/doi.org\/10.1164\/rccm.200909-1420OC","DOI":"10.1164\/rccm.200909-1420OC"},{"key":"bibr16-1076029620936776","doi-asserted-by":"crossref","unstructured":"Mukhopadhyay S, Philip AT, Stoppacher R. Pathologic findings in novel influenza A (H1N1) virus (\u201cSwine Flu\u201d) infection: contrasting clinical manifestations and lung pathology in two fatal cases. Am J Clin Pathol. 2010;133(3):380\u2013387. https:\/\/doi.org\/10.1309\/AJCPXY17SULQKSWK","DOI":"10.1309\/AJCPXY17SULQKSWK"},{"key":"bibr17-1076029620936776","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0907171"},{"issue":"5","key":"bibr18-1076029620936776","first-page":"623","volume":"55","author":"Gilbert CR","year":"2010","journal-title":"Respir Care"},{"key":"bibr19-1076029620936776","doi-asserted-by":"crossref","unstructured":"Bunce PE, High SM, Nadjafi M, Stanley K, Liles WC, Christian MD. Pandemic H1N1 influenza infection and vascular thrombosis. Clin Infect Dis 2011;52(2):e14\u2013e17. https:\/\/doi.org\/10.1093\/cid\/ciq125","DOI":"10.1093\/cid\/ciq125"},{"key":"bibr20-1076029620936776","doi-asserted-by":"crossref","unstructured":"Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054\u20131062. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"bibr21-1076029620936776","doi-asserted-by":"crossref","unstructured":"Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past.\n                      J\n                      Clin Virol. 2020;127:104362. https:\/\/doi.org\/10.1016\/j.jcv.2020.104362","DOI":"10.1016\/j.jcv.2020.104362"},{"key":"bibr22-1076029620936776","doi-asserted-by":"crossref","unstructured":"Goeijenbier M, van Wissen M, van de Weg C, et al. Review: Viral infections and mechanisms of thrombosis and bleeding. J Med Virol. 2012;84(10):1680\u20131696. https:\/\/doi.org\/10.1002\/jmv.23354","DOI":"10.1002\/jmv.23354"},{"key":"bibr23-1076029620936776","doi-asserted-by":"crossref","unstructured":"Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Eng J Med. 2020;382(17):e38. https:\/\/doi.org\/10.1056\/NEJMc2007575","DOI":"10.1056\/NEJMc2007575"},{"key":"bibr24-1076029620936776","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.083410"},{"key":"bibr25-1076029620936776","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1710019"},{"key":"bibr26-1076029620936776","doi-asserted-by":"crossref","unstructured":"Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Hemost. 2020;18(5):1094-1099. https:\/\/doi.org\/10.1111\/jth.14817","DOI":"10.1111\/jth.14817"},{"issue":"2","key":"bibr27-1076029620936776","first-page":"414","volume":"11","author":"Li J","year":"2018","journal-title":"Int J Clin Exp Med"},{"key":"bibr28-1076029620936776","doi-asserted-by":"crossref","unstructured":"Shi C, Wang C, Wang H, et al. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.28.20046144","DOI":"10.1101\/2020.03.28.20046144"},{"key":"bibr29-1076029620936776","doi-asserted-by":"crossref","unstructured":"Thachil J. The versatile heparin in COVID-19. J Thromb Hemost. 2020;18(5):1020\u20131022. https:\/\/doi.org\/10.1111\/jth.14821","DOI":"10.1111\/jth.14821"},{"key":"bibr30-1076029620936776","doi-asserted-by":"crossref","unstructured":"Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2008;122(6):743-752. https:\/\/doi.org\/10.1016\/j.thromres.2006.10.026","DOI":"10.1016\/j.thromres.2006.10.026"},{"issue":"5","key":"bibr31-1076029620936776","first-page":"823","volume":"102","author":"Li JP","year":"2009","journal-title":"Thromb Haemost"},{"key":"bibr32-1076029620936776","doi-asserted-by":"crossref","unstructured":"Shukla D, Spear PG. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J Clin Invest. 2001;108(4):503\u2013510. https:\/\/doi.org\/10.1172\/JCI13799","DOI":"10.1172\/JCI200113799"},{"key":"bibr33-1076029620936776","doi-asserted-by":"crossref","unstructured":"Ghezzi S, Cooper L, Rubio A, et al. Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. Antiviral Res. 2017;140:13\u201317. https:\/\/doi.org\/10.1016\/j.antiviral.2016.12.023","DOI":"10.1016\/j.antiviral.2016.12.023"},{"key":"bibr34-1076029620936776","doi-asserted-by":"crossref","unstructured":"Cohoon KP, Mah\u00e9 G, Tafur AJ, Spyropoulos AC. Emergence of institutional antithrombotic protocols for coronavirus 2019. Res Practice Thromb Haemost. 2020;4(4):510\u2013517. https:\/\/doi.org\/10.1002\/rth2.12358","DOI":"10.1002\/rth2.12358"},{"key":"bibr35-1076029620936776","doi-asserted-by":"crossref","unstructured":"Bendstrup KE, Chambers CB, Jensen JI, Newhouse MT. Lung deposition and clearance of inhaled (99 m)Tc-heparin in healthy volunteers. Am J Resp Crit Care Med. 1999;160(5 Pt 1):1653\u20131658. https:\/\/doi.org\/10.1164\/ajrccm.160.5.9809123","DOI":"10.1164\/ajrccm.160.5.9809123"},{"key":"bibr36-1076029620936776","doi-asserted-by":"crossref","unstructured":"Bandeshe H, Boots R, Dulhunty J, et al. Is inhaled prophylactic heparin useful for prevention and management of pneumonia in ventilated ICU patients? The IPHIVAP investigators of the Australian and New Zealand Intensive Care Society Clinical Trials Group. J Crit Care. 2016;34:95\u2013102. https:\/\/doi.org\/10.1016\/j.jcrc.2016.04.005","DOI":"10.1016\/j.jcrc.2016.06.021"},{"key":"bibr37-1076029620936776","doi-asserted-by":"crossref","unstructured":"Bendstrup KE, Gram J, Jensen JI. Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur Resp J. 2002;19(4):606\u2013610. https:\/\/doi.org\/10.1183\/09031936.02.00105202","DOI":"10.1183\/09031936.02.00105202"},{"key":"bibr38-1076029620936776","doi-asserted-by":"crossref","unstructured":"Ghiasi F, Sadeghian M, Emami M, Kiaie BA, Mousavi SA. Pilot study of nebulized heparin for prevention of ventilator induced lung injury: comparative effects with an inhaled corticosteroid. Indian j crit care med. 2017;21(10):634\u2013639. https:\/\/doi.org\/10.4103\/ijccm.IJCCM_183_17","DOI":"10.4103\/ijccm.IJCCM_183_17"},{"key":"bibr39-1076029620936776","doi-asserted-by":"crossref","unstructured":"Dixon B, Santamaria JD, Campbell DJ. A phase 1 trial of nebulised heparin in acute lung injury. Crit care. 2008;12(3):R64. https:\/\/doi.org\/10.1186\/cc6894","DOI":"10.1186\/cc6894"},{"key":"bibr40-1076029620936776","doi-asserted-by":"crossref","unstructured":"McIntire A, Harris S, Whitten J, et al. Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study). J Intensive Care Soci. 2018;19(1):80\u201382. https:\/\/doi.org\/10.1177\/1751143717737408","DOI":"10.1177\/1751143717737408"},{"key":"bibr41-1076029620936776","doi-asserted-by":"crossref","unstructured":"Shute JK, Calzetta L, Cardaci V, di Toro S, Page CP, Cazzola M. Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: a pilot study. Pulm Pharmacol Ther. 2018;48:88\u201396. https:\/\/doi.org\/10.1016\/j.pupt.2017.10.001","DOI":"10.1016\/j.pupt.2017.10.001"},{"key":"bibr42-1076029620936776","doi-asserted-by":"crossref","unstructured":"Yip LY, Lim YF, Chan HN. Safety and potential anticoagulant effects of nebulised heparin in burns patients with inhalational injury at Singapore General Hospital Burns Centre. Burns. 2011;37(7):1154\u20131160. https:\/\/doi.org\/10.1016\/j.burns.2011.07.006","DOI":"10.1016\/j.burns.2011.07.006"},{"key":"bibr43-1076029620936776","doi-asserted-by":"crossref","unstructured":"Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Hemost. 2020. https:\/\/doi.org\/10.1111\/jth.14828","DOI":"10.1111\/jth.14828"},{"key":"bibr44-1076029620936776","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0000000000002694"},{"key":"bibr45-1076029620936776","doi-asserted-by":"crossref","unstructured":"Lowe GD. Virchow\u2019s triad revisited: abnormal flow. Pathophysiol Haemost Thromb. 2003;33(5-6\n                      )\n                      :455\u2013457. https:\/\/doi.org\/10.1159\/000083845","DOI":"10.1159\/000083845"},{"key":"bibr46-1076029620936776","doi-asserted-by":"crossref","unstructured":"Sachdeva A, Dalton M, Amaragiri SV, Lees T. Graduated compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev. 2014;12:CD001484. https:\/\/doi.org\/10.1002\/14651858.CD001484.pub3","DOI":"10.1002\/14651858.CD001484.pub3"},{"key":"bibr47-1076029620936776","doi-asserted-by":"crossref","unstructured":"Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed:\n                      American College of Chest Physicians Evidence-Based Clinical Practice Guidelines\n                      . Chest. 2012\n                      ;\n                      141(2):e195S\u2013e226S. https:\/\/doi.org\/10.1378\/chest.11-2296","DOI":"10.1378\/chest.141.6.1645"},{"key":"bibr48-1076029620936776","doi-asserted-by":"crossref","unstructured":"Griffin M, Nicolaides AN, Bond D, Geroulakos G, Kalodiki E. The efficacy of a new stimulation technology to increase flow and prevent venous stasis. Eur J Vasc Endovasc Surg. 2010;40(6):766\u2013771 https:\/\/doi.org\/10.1016\/j.ejvs.2010.06.019","DOI":"10.1016\/j.ejvs.2010.06.019"},{"key":"bibr49-1076029620936776","doi-asserted-by":"crossref","unstructured":"Lattimer CR, Azzam M, Papaconstandinou JA, Villasin M, Ash S, Kalodiki E. Neuromuscular electrical stimulation reduces sludge in the popliteal vein. J Vasc Surg Lymphat Disord. 2018;6(2):154\u2013162. https:\/\/doi.org\/10.1016\/j.jvsv.2017.09.008","DOI":"10.1016\/j.jvsv.2017.09.008"},{"key":"bibr50-1076029620936776","doi-asserted-by":"crossref","unstructured":"Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. 2020. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047430","DOI":"10.1161\/CIRCULATIONAHA.120.047430"},{"key":"bibr51-1076029620936776","unstructured":"FDA. 2020. https:\/\/www.fda.gov\/vaccines-blood-biologics\/investigational-new-drug-ind-or-device-exemption-ide-proc (accessed 29 April, 2020)."},{"key":"bibr52-1076029620936776","doi-asserted-by":"crossref","unstructured":"Rajendran K, Narayanasamy K, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.25961","DOI":"10.1002\/jmv.25961"},{"key":"bibr53-1076029620936776","doi-asserted-by":"crossref","unstructured":"Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490\u20139496. https:\/\/doi.org\/10.1073\/pnas.2004168117","DOI":"10.1073\/pnas.2006961117"},{"key":"bibr54-1076029620936776","doi-asserted-by":"crossref","unstructured":"Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582\u20131589. https:\/\/doi.org\/10.1001\/jama.2020.4783","DOI":"10.1001\/jama.2020.4783"},{"key":"bibr55-1076029620936776","doi-asserted-by":"crossref","unstructured":"Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infectious Dis. 2020;20(4):398\u2013400. https:\/\/doi.org\/10.1016\/S1473-3099(20)30141-30149","DOI":"10.1016\/S1473-3099(20)30141-9"},{"key":"bibr56-1076029620936776","author":"Zhong X","year":"2020","journal-title":"Zhonghua Hanghai Yixue yu Gaoqiya Yixue Zazhi"},{"key":"bibr57-1076029620936776","unstructured":"Zhong XL, Niu XQ, Tao XL, Chen RY, Liang Y, Tang YC. The first case of HBOT in critically ill endotracheal intubation patient with COVID-19. Novel Coronavirus Pneumonia Research Network Sharing Platform of China Association for Science and Technology; 2020"},{"key":"bibr58-1076029620936776","doi-asserted-by":"crossref","unstructured":"Liu X, Li Z, Liu S, et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B. 2020;2211\u20133835. https:\/\/doi.org\/10.1016\/j.apsb.2020.04.008","DOI":"10.1016\/j.apsb.2020.04.008"},{"key":"bibr59-1076029620936776","doi-asserted-by":"crossref","unstructured":"Wei J, Huang F, Xiong T, et al. Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis. Heart. 2020. http:\/\/dx.doi.org\/10.1136\/heartjnl-2020-317007","DOI":"10.1136\/heartjnl-2020-317007"},{"key":"bibr60-1076029620936776","doi-asserted-by":"crossref","unstructured":"Cheng R, Leedy D. COVID-19 and acute myocardial injury: the heart of the matter or an innocent bystander? Heart. 2020. http:\/\/dx.doi.org\/10.1136\/heartjnl-2020-317025","DOI":"10.1136\/heartjnl-2020-317025"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029620936776","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1076029620936776","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029620936776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:04:12Z","timestamp":1777385052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1076029620936776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":60,"alternative-id":["10.1177\/1076029620936776"],"URL":"https:\/\/doi.org\/10.1177\/1076029620936776","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,1]]},"article-number":"1076029620936776"}}